default Why the treatment of early psychosis is such a promising area for clinical trials

The Cadence team at Queensland Centre for Mental Health Research are ready to help build clinical trials platforms in Australia. QCMHR Director, Professor John McGrath explains why the treatment of early psychosis is such a promising area for clinical trials.

Funded by the John Cade Fellowship, and in collaboration with Associate Professor James Scott, the Epidemiology and Clinical Trials Group, alongside staff from the Queensland Brain Institute, have linked up with clinicians around south-east Queensland to commence the Cadence clinical trials program. The aim of the Cadence program is to conduct randomised control trials of new candidate treatments for those with psychosis.